Carcinoid-syndrome: recent advances, current status and controversies.
Ito T, Lee L, Jensen RT.
Curr Opin Endocrinol Diabetes Obes. 2018 Feb;25(1):22-35. doi: 10.1097/MED.0000000000000376.
Carcinoid Syndrome: Preclinical Models and Future Therapeutic Strategies.
Vitale G, Carra S, Alessi Y, Campolo F, Pandozzi C, Zanata I, Colao A, Faggiano A, On Behalf Of The Nike Group.
Int J Mol Sci. 2023 Feb 10;24(4):3610. doi: 10.3390/ijms24043610.
Carcinoid syndrome: update on the pathophysiology and treatment.
Rubin de Celis Ferrari AC, Glasberg J, Riechelmann RP.
Clinics (Sao Paulo). 2018 Aug 20;73(suppl 1):e490s. doi: 10.6061/clinics/2018/e490s.
Carcinoid Syndrome: Updates and Review of Current Therapy.
Oleinikov K, Avniel-Polak S, Gross DJ, Grozinsky-Glasberg S.
Curr Treat Options Oncol. 2019 Jul 9;20(9):70. doi: 10.1007/s11864-019-0671-0.
Carcinoid syndrome-Symptoms and therapeutic approaches.
Chrisoulidou A.
Hell J Nucl Med. 2023 May-Aug;26 Suppl:52-56.
Recent Advances in the Diagnosis and Management of Carcinoid Syndrome.
Subash N, Papali MM, Bahadur KP, Avanthika C, Jhaveri S, Thannir S, Joshi M, Valisekka SS.
Dis Mon. 2022 Jul;68(7):101304. doi: 10.1016/j.disamonth.2021.101304. Epub 2021 Dec 28.
Carcinoid syndrome.
Bendelow J, Apps E, Jones LE, Poston GJ.
Eur J Surg Oncol. 2008 Mar;34(3):289-96. doi: 10.1016/j.ejso.2007.07.202. Epub 2007 Dec 18.
Carcinoid syndrome.
Tilson MD.
Surg Clin North Am. 1974 Apr;54(2):409-23. doi: 10.1016/s0039-6109(16)40288-4.
Serotonin pathway in carcinoid syndrome: Clinical, diagnostic, prognostic and therapeutic implications.
Fanciulli G, Ruggeri RM, Grossrubatscher E, Calzo FL, Wood TD, Faggiano A, Isidori A, Colao A; NIKE.
Rev Endocr Metab Disord. 2020 Dec;21(4):599-612. doi: 10.1007/s11154-020-09547-8.
New Treatments for the Carcinoid Syndrome.
Loughrey PB, Zhang D, Heaney AP.
Endocrinol Metab Clin North Am. 2018 Sep;47(3):557-576. doi: 10.1016/j.ecl.2018.04.014. Epub 2018 Jul 11.
